Mark A. Green
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark A. Green has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Carla J. Mathias
5 shared publications- Nathan E. Basken
Division of Nuclear Pharmacy, Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana, USA
2 shared publications Alexander E. Lipka
Department of Statistics, Purdue University, West Lafayette, IN 47907, USA
1 shared publication- Barry A. Siegel
Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, USA
1 shared publication Carla J Mathias
1 shared publication- David M. Gershenson
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
1 shared publication
Latest Publications
- 1 July 2009
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 36 (5) , 495-504
Cu(II) bis(thiosemicarbazone) radiopharmaceutical binding to serum albumin: further definition of species dependence and associated substituent effects
- 1 July 2009
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 36 (5) , 495-504
Cu(II) bis(thiosemicarbazone) radiopharmaceutical binding to serum albumin: further definition of species dependence and associated substituent effects
- 1 June 2009
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 98 (6) , 2170-2179
Elucidation of the human serum albumin (HSA) binding site for the Cu-PTSM and Cu-ATSM radiopharmaceuticals
- 1 June 2009
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 98 (6) , 2170-2179
Elucidation of the human serum albumin (HSA) binding site for the Cu-PTSM and Cu-ATSM radiopharmaceuticals
- 1 December 2008
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 66 (12) , 1910-1912
A convenient route to [68Ga]Ga-MAA for use as a particulate PET perfusion tracer
- 1 December 2008
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 66 (12) , 1910-1912
A convenient route to [68Ga]Ga-MAA for use as a particulate PET perfusion tracer
- 30 January 2008
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 35 (3) , 281-286
Species dependence of [64Cu]Cu-Bis(thiosemicarbazone) radiopharmaceutical binding to serum albumins
- 30 January 2008
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 35 (3) , 281-286
Species dependence of [64Cu]Cu-Bis(thiosemicarbazone) radiopharmaceutical binding to serum albumins
- 1 April 2007
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 34 (3) , 247-255
Assessment of Cu-ETS as a PET radiopharmaceutical for evaluation of regional renal perfusion
- 1 April 2007
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 34 (3) , 247-255
Assessment of Cu-ETS as a PET radiopharmaceutical for evaluation of regional renal perfusion
- 1 May 2003
- Vol. 44 (5) , 700-7
Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results.
The cell-membrane folate receptor is a potential molecular target for tumor-selective drug delivery, including radiolabeled folate-chelate conjugates for diagnostic imaging. We report here the initial clinical study of such an agent, (111)In-diethylenetriaminepentaacetic acid (DTPA)-folate, evaluated for diagnosis of ovarian malignancy. Thirty-five women were enrolled in a phase I/II clinical study, with 33 completing the surgical follow-up required by the study protocol for definition of disease status. Patients either had a pathologically proven malignancy or were scheduled for surgery for suspected new ovarian cancer (n = 26), recurrent ovarian cancer (n = 5), or endometrial cancer (n = 2). (111)In-DTPA-folate was administered as an intravenous bolus, and whole-body images were obtained at 30 min, 4 h, and (for the first 19 patients) 24 h after injection; SPECT also was done at the delayed imaging times. For 19 of the patients, unlabeled free folic acid was injected before administration of (111)In-DTPA-folate to also assess the impact of folate loading on tracer biodistribution. Masked and unmasked readings of the images by 2 nuclear medicine physicians were compared with the pathologic findings after surgery. Among 33 patients who had surgical intervention, 14 had new or recurrent malignant tumors. All of 7 newly diagnosed ovarian carcinomas were identified by both masked readers (sensitivity, 100%). The sensitivity for detection of 7 recurrent malignancies was 38% for masked readings and 85% for unmasked readings, indicating that correlation with anatomic imaging studies (CT) was highly important in diagnosis of these lesions. Eighteen of the studied patients were found to have benign masses; for this limited population, the specificity of (111)In-DTPA-folate scintigraphy was 76% and 82% for the masked and unmasked analyses, respectively. (111)In-DTPA-folate is safe, and possibly effective, for scintigraphy differentiating between malignant and benign ovarian masses.
- 1 May 2003
- Vol. 44 (5) , 700-7
Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results.
The cell-membrane folate receptor is a potential molecular target for tumor-selective drug delivery, including radiolabeled folate-chelate conjugates for diagnostic imaging. We report here the initial clinical study of such an agent, (111)In-diethylenetriaminepentaacetic acid (DTPA)-folate, evaluated for diagnosis of ovarian malignancy. Thirty-five women were enrolled in a phase I/II clinical study, with 33 completing the surgical follow-up required by the study protocol for definition of disease status. Patients either had a pathologically proven malignancy or were scheduled for surgery for suspected new ovarian cancer (n = 26), recurrent ovarian cancer (n = 5), or endometrial cancer (n = 2). (111)In-DTPA-folate was administered as an intravenous bolus, and whole-body images were obtained at 30 min, 4 h, and (for the first 19 patients) 24 h after injection; SPECT also was done at the delayed imaging times. For 19 of the patients, unlabeled free folic acid was injected before administration of (111)In-DTPA-folate to also assess the impact of folate loading on tracer biodistribution. Masked and unmasked readings of the images by 2 nuclear medicine physicians were compared with the pathologic findings after surgery. Among 33 patients who had surgical intervention, 14 had new or recurrent malignant tumors. All of 7 newly diagnosed ovarian carcinomas were identified by both masked readers (sensitivity, 100%). The sensitivity for detection of 7 recurrent malignancies was 38% for masked readings and 85% for unmasked readings, indicating that correlation with anatomic imaging studies (CT) was highly important in diagnosis of these lesions. Eighteen of the studied patients were found to have benign masses; for this limited population, the specificity of (111)In-DTPA-folate scintigraphy was 76% and 82% for the masked and unmasked analyses, respectively. (111)In-DTPA-folate is safe, and possibly effective, for scintigraphy differentiating between malignant and benign ovarian masses.
- Open Access
- 1 January 1985
- Published by Japan Radioisotope Association in RADIOISOTOPES
- Vol. 34 (3) , 170-179
Radiopharmaceuticals labeled with short-lived positron-emitting radionuclides.
- 1 January 1985
- Published by Japan Radioisotope Association in RADIOISOTOPES
- Vol. 34 (3) , 170-179
Open AccessRadiopharmaceuticals labeled with short-lived positron-emitting radionuclides.